Allosteric mechanism of action of the therapeutic anti-IgE antibody omalizumab

Immunoglobulin E and its interactions with receptors FcϵRI and CD23 play a central role in allergic disease. Omalizumab, a clinically approved therapeutic antibody, inhibits the interaction between IgE and FcϵRI, preventing mast cell and basophil activation, and blocks IgE binding to CD23 on B cells...

Full description

Saved in:
Bibliographic Details
Published in:J Biol Chem
Main Authors: Davies, Anna M., Allan, Elizabeth G., Keeble, Anthony H., Delgado, Jean, Cossins, Benjamin P., Mitropoulou, Alkistis N., Pang, Marie O. Y., Ceska, Tom, Beavil, Andrew J., Craggs, Graham, Westwood, Marta, Henry, Alistair J., McDonnell, James M., Sutton, Brian J.
Format: Artigo
Language:Inglês
Published: American Society for Biochemistry and Molecular Biology 2017
Subjects:
Immunology
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5473249/
https://ncbi.nlm.nih.gov/pubmed/28438838
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1074/jbc.M117.776476
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items